Esomeprazole vs Lansoprazole
## Overview
Esomeprazole and lansoprazole are both modern PPIs with high acid suppression efficacy. Esomeprazole achieves higher AUC (as the pure S-enantiomer of omeprazole), while lansoprazole offers convenient orally disintegrating tablet (SoluTab) formulation.
## Mechanism of Action
Both irreversibly inhibit parietal cell H+/K+-ATPase via covalent sulfenamide binding after acid-dependent activation.
## Pharmacokinetics
Esomeprazole: S-enantiomer, higher AUC, CYP2C19 (less than R-omeprazole). Lansoprazole: balanced CYP2C19/CYP3A4 metabolism. Both ~1–1.5 h half-life with prolonged pharmacodynamic effect.
## Clinical Evidence
Esomeprazole 40 mg heals erosive esophagitis at rates of 90–94% at 8 weeks, comparable or slightly superior to lansoprazole 30 mg. Direct head-to-head trials show modest advantages for esomeprazole in severe GERD (LA Grade C/D). For mild GERD and PUD, both are equivalent.
## Drug Interactions
Both inhibit CYP2C19 (esomeprazole ≥ lansoprazole); neither is preferred over pantoprazole with clopidogrel.
## Key Takeaways
- Esomeprazole: higher AUC, slightly superior in severe GERD
- Lansoprazole: SoluTab for dysphagia; not superior overall
- Both CYP2C19 inhibitors; prefer pantoprazole with clopidogrel
निष्कर्ष
Esomeprazole has a modest efficacy advantage in severe erosive esophagitis. Lansoprazole is preferred in patients with dysphagia who need an ODT formulation. For mild-to-moderate GERD and PUD, both are clinically equivalent.